140 related articles for article (PubMed ID: 32688293)
1. Prognosis of patients with muscle invasive bladder cancer who are intolerable to receive any anti-cancer treatment.
Ogawa K; Shimizu Y; Uketa S; Utsunomiya N; Kanamaru S
Cancer Treat Res Commun; 2020; 24():100195. PubMed ID: 32688293
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
3. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
Zhang J; Zhou X; Ding H; Wang L; Liu S; Liu Y; Chen Z
BMC Urol; 2020 Mar; 20(1):31. PubMed ID: 32192483
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer.
Zhiyu Z; Qi Z; Zhen S; Jun O; Jianglei Z
Technol Cancer Res Treat; 2021; 20():15330338211062323. PubMed ID: 34816789
[No Abstract] [Full Text] [Related]
6. Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer.
Elshabrawy A; Wang H; Satsangi A; Wheeler K; Ramamurthy C; Pruthi D; Kaushik D; Liss M; Gelfond J; Fernandez R; Gore J; Svatek R; Mansour AM
Urol Oncol; 2021 Apr; 39(4):236.e9-236.e20. PubMed ID: 33423936
[TBL] [Abstract][Full Text] [Related]
7. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
[TBL] [Abstract][Full Text] [Related]
9. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
Ecke TH; Stier K; Weickmann S; Zhao Z; Buckendahl L; Stephan C; Kilic E; Jung K
Cancer Med; 2017 Oct; 6(10):2252-2262. PubMed ID: 28879675
[TBL] [Abstract][Full Text] [Related]
10. The natural history of untreated muscle-invasive bladder cancer.
Martini A; Sfakianos JP; Renström-Koskela L; Mortezavi A; Falagario UG; Egevad L; Hosseini A; Mehrazin R; Galsky MD; Steineck G; Wiklund NP
BJU Int; 2020 Feb; 125(2):270-275. PubMed ID: 31310696
[TBL] [Abstract][Full Text] [Related]
11. Use of preoperative performance status and hemoglobin concentration to predict overall survival for patients aged ≥ 75 years after radical cystectomy for treatment of bladder cancer.
Hara T; Matsuyama H; Kamiryo Y; Hayashida S; Yamamoto N; Nasu T; Joko K; Baba Y; Suga A; Yamamoto M; Aoki A; Takai K; Yoshihiro S; Konishi M; Sakano S; Imoto K; Tei Y; Yamaguchi S; Yano S;
Int J Clin Oncol; 2016 Feb; 21(1):139-47. PubMed ID: 26077140
[TBL] [Abstract][Full Text] [Related]
12. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.
Kaushik D; Wang H; Michalek J; Liss MA; Liu Q; Jha RP; Svatek RS; Mansour AM
Urology; 2019 Nov; 133():164-174. PubMed ID: 31401220
[TBL] [Abstract][Full Text] [Related]
14. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
15. The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients.
Aizawa R; Sakamoto M; Orito N; Kono M; Ogura M; Negoro Y; Sagoh T; Tsukahara K; Komatsu K; Noguchi M
Anticancer Res; 2017 Oct; 37(10):5761-5766. PubMed ID: 28982898
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
[TBL] [Abstract][Full Text] [Related]
18. Radical radiotherapy in older patients with muscle invasive bladder cancer.
Wujanto C; Tey J; Chia D; Ho F; Ooi KH; Wong AS; Soon YY; Lim K
J Geriatr Oncol; 2019 Mar; 10(2):292-297. PubMed ID: 30630748
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N
Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195
[TBL] [Abstract][Full Text] [Related]
20. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
